



MPM IMPACT INVESTING

MPM is helping to advance cancer research and care through its innovative approach to investing and its partnerships with the American Association for Cancer Research, the UBS Optimus Foundation and Dana-Farber Cancer Institute

[LEARN MORE](#)

OUR FOCUS

MPM Capital is a healthcare investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals and Executive Partners, MPM strives to power novel medical breakthroughs that transform patients' lives.

MAKING AN IMPACT THROUGH INNOVATION

MPM continuously seeks new ways to invest in order to drive breakthroughs and cures, and two of its investment vehicles feature innovative impact components:

- The first is the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM that donates a portion of profits and royalties to cancer care and research. Through its partnership with the American Association of Cancer Research, the first gift of \$1.2 million was made in 2018 to the joint AACR-MPM Transformative Cancer Research Grants Program. An equal amount was also donated to the UBS Optimus Foundation to support emerging market access to cancer care.
- The second features a philanthropy-investment opportunity involving Dana-Farber Cancer Institute (DFCI) to advance cancer research. This unique philanthropy-investment opportunity gives MPM early insight into DFCI projects with commercial potential and provides DFCI with potential new philanthropic resources.



Alinea
Pharmaceuticals

Allozyne, Inc.



Archus
Orthopedics, Inc.



ATOPIX

 **Barrier** Therapeutics, Inc.

BLADE 
THERAPEUTICS

 Celladon


CELLERANT
THERAPEUTICS

 cerecor
INC

Ceregene, Inc.

Cerimon
Pharmaceuticals

CHF Solutions

 CHIASMA

Clinical 
ink®

 CODA
BIOTHERAPEUTICS

Ceretyx

 Cerini

Conatus
Pharmaceuticals 

 **CoStim**
PHARMACEUTICALS

COTHERIX


cullinan
ONCOLOGY

DigiTx Partners


Dragonfly
SCIENCES

 **Dyne**
THERAPEUTICS

EKR
THERAPEUTICS

elevatebio 

 **ELIXIR**
PHARMACEUTICALS

 EndoGastric Solutions

 **Endologix**

EnteroMedics

 **entrada**
THERAPEUTICS



Innovative
Spinal
Technologies



Intracel
Holdings
Corporation







Radius®

Raze Therapeutics

REPAIR
THERAPEUTICS


rhythm

RIGEL®


RINAT

sai 
solutions that add up

 SELEXYS
PHARMACEUTICALS

semma
THERAPEUTICS


 **SIDERIS**
PHARMACEUTICALS

Solasia

Somaxon
PHARMACEUTICALS

Surface
Logix

Syndax 

 **TCR²**
THERAPEUTICS

 Tercica

Tetherex
Pharmaceuticals
Corporation

THERACLONE 
SCIENCES


TIZONA
THERAPEUTICS

 **TRIEZA**
THERAPEUTICS

TriNetx


TRUE NORTH
THERAPEUTICS

VACCINOGEN

valeritas 



Role Investment Team Executive Partners and Entrepreneurs Advisors Operations Team

Location All Cambridge San Francisco



Patrick A. Baeuerle



Chris Bardon



Vinay Bhaskar



Detlev Biniszkiwicz



Lauren Cauley



Scott Chappel



Stephen Curtis



Thomas Ebeling



Stephen Elledge



Luke Evnin



Mitchell Finer



Todd Foley



Shinichiro Fuse



Ansbert Gadicke



Brian Goodman



William Greene



William Hahn



David Hallal



Dan Hicklin



Robert Horvitz



Owen Hughes



Ed Hurwitz



Kristen Laguerre



Nicholas (Nick)
McGrath, J.D.



Briggs Morrison



Gary Patou



Devin Quinlan



Tony Rosenberg



Howard Rubin



David Ryan



Greg Sieczkiewicz



Vikas Sinha



Elizabeth Stoner



Leigh Zawel

CONTACT US

THE SAN FRANCISCO OFFICE HAS MOVED 1 MILE NORTH TO BRISBANE TO THE LOCATION SHOWN BELOW

info@mpmcapital.com

CAMBRIDGE, MA

450 Kendall Street
Cambridge, MA 02142

Phone | 617-425-9200



[GET DIRECTIONS](#)

BRISBANE, CA **NEW ADDRESS**

2000 Sierra Point Parkway, Suite 701
Brisbane, CA 94005

Phone | 650-553-3300



[GET DIRECTIONS](#)

[TERMS OF USE & DISCLOSURES](#)

[PRINT](#)

2019 2018 2017 2016 2015 2014



BACK TO TOP

Copyright © 2019 MPM Capital, Inc.

